Is Halozyme Therapeutics (HALO) a Buy Post Earnings?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best cheap biotech stocks to buy now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received several bullish rating updates from analysts following its earnings release. Morgan Stanley lifted the price target on the stock to $94 from $78 on February 19, maintaining an Overweight rating on the shares after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported “strong” Q4 results. It told investors in a research note that it believes 2026 to be “another st ...